Splash Beverage Files to Sell 10M Shares of Common Stock
Splash Beverage files to sell 10M shares of common stock for holders
Trade with 70% Backtested Accuracy
Analyst Views on SBEV
About SBEV
About the author

- Market Growth Potential: The functional market is projected to expand from $164 billion to over $240 billion, indicating strong consumer demand for utility-driven products, positioning Doseology at the forefront of this high-growth cycle.
- New Product Pilot: Doseology initiated pilot production of caffeine-based energy pouches in January 2026, utilizing nicotine-free portable packaging to meet consumer demand for healthier alternatives, which is expected to significantly enhance market competitiveness.
- Strategic Brand Acquisition: Doseology acquired the Feed That Brain brand for $400,000, integrating functional product design with market trends to strengthen its position in the energy drink and alternative caffeine product sectors.
- Executive Recruitment: The company appointed Joseph Mimran as Strategic Advisor with a three-year contract valued at $400,000, aiming to leverage his extensive retail experience to drive Doseology's product development and market expansion.
- Market Surge: The global functional beverage market is projected to reach $179.26 billion by 2026, driven by health-conscious consumers shifting away from high-sugar drinks, indicating a structural reset that attracts significant capital inflow.
- New Product Pilot: Doseology Sciences launched pilot production of non-nicotine, caffeine-based energy pouches in January 2026, emphasizing predictable energy delivery to meet modern consumer demands for portable, functional beverages, which is expected to enhance market competitiveness.
- Strategic Acquisition: Doseology acquired the Feed That Brain brand for $400,000, further expanding its footprint in the functional market while appointing Joseph Mimran as Strategic Advisor to bolster product development and compliance capabilities, supporting future growth.
- Industry Collaboration: Splash Beverage Group entered a joint venture with BAAD Ventures to tap into the rapidly expanding THC beverage market, leveraging both companies' distribution networks and brand-building expertise, which is expected to significantly enhance market share and supply chain efficiencies.
Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.
Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.
Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.
Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.
Stock Performance: Splash Beverage Group Inc. (SBEV) shares surged 40.52% in after-hours trading to $1.05, despite closing down 17.25% at $0.75 during regular trading. The stock has fallen 91.1% over the past year.
Financial Results: The company reported no net revenue for Q3, down from $981,858 the previous year, and a net loss of $9.89 million, equating to a $4.51 loss per share.
Water Rights Acquisition: In June, SBEV acquired water extraction rights to a Costa Rican aquifer valued at $20 million, issuing 20,000 shares of Series C preferred stock in the transaction.
Capital Structure Changes: Total assets increased to $22.49 million as of Sept. 30, with stockholders' equity turning positive at $6.78 million, compared to a previous deficit of $18.63 million.
New Chairman Appointment: Oligomerix, Inc. has elected William Caple as the new Chairman of the Board, bringing over 30 years of executive leadership experience to the role, particularly in corporate investment and business development.
Focus on Alzheimer's Treatment: Oligomerix is advancing its lead compound, OLX-07010, through Phase 1 clinical testing, targeting tau protein accumulation to address Alzheimer's disease and other rare neurodegenerative disorders.
Stock Market Performance: This week, the S&P 500 rose by 0.73%, while the Dow Jones Industrial Average and Nasdaq 100 fell by 0.71% and 0.08%, respectively, amid mixed market conditions due to Good Friday closures.
Market Volatility: High volatility continues in the stock market, particularly affecting penny stocks, as economic uncertainty and trade tensions persist, influencing both gains and losses across various indices and ETFs.









